ESC Professional Premium Access

How to deal with residual cardiovascular risk in atherosclerotic disease? New pharmacotherapeutic options

Event: ESC Congress 2022
Topic: Cardiovascular Pharmacotherapy
Session type: Symposium
Date: 29 August 2022
Time: 14:00 - 15:15

Congress Session

Become an ESC Professional member to access this resource

Become a member

Already a member? Sign in

5 presentations in this session

Residual risk in dyslipidaemias: from statins to PCSK9 inhibitors and beyond.

Speaker: Professor E. Stroes (Amsterdam, NL)
Thumbnail

Residual inflammatory risk.

Speaker: Professor W. Koenig (Munich, DE)
Thumbnail

Residual thrombotic risk: from monotherapy to dual pathway inhibition.

Speaker: Associate Professor B. Rocca (Rome, IT)
Thumbnail

Residual diabetic risk: from glucose lowering to cardiovascular protection.

Speaker: Professor N. Marx (Aachen, DE)
Thumbnail

How to deal with residual cardiovascular risk in atherosclerotic disease? New pharmacotherapeutic options – discussion.

Thumbnail

4 speakers from this session

Professor Erik Stroes

Academic Medical Centre, Amsterdam (Netherlands (The))
24 presentations
0 follower

Professor Wolfgang Koenig

German Heart Center of Munich, Munich (Germany)
23 presentations
0 follower

Associate Professor Bianca Rocca

Catholic University School of Medicine, Rome (Italy)
7 presentations
0 follower

Professor Nikolaus Marx

RWTH University Hospital Aachen, Aachen (Germany)
28 presentations
1 follower

This platform is supported by

logo Novo Nordisk